The authors sought to assess the clinical outcomes of left atrial appendage (LAA) closure with the LAmbre closure system in patients with nonvalvular atrial fibrillation (NVAF).
age-matched population in sinus rhythm (2) . There is a great deal of published reports on stroke prevention demonstrating that oral anticoagulation with warfarin is the current most common and effective therapy to prevent stroke associated with AF (3) (4) (5) . Unfortunately, this treatment is generally underused due to its several limitations, including the narrow therapeutic window, the drug and food interactions, the need for repeated monitoring, and the poor patient tolerance.
Autopsy and echocardiography studies have shown that more than 90% of atrial thrombi in patients with NVAF locate in the left atrial appendage (LAA) (6, 7) . Therefore, percutaneous LAA closure has been devel- 
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LAmbre Prevents Stroke in AF 2189 physician. The distal umbrella was released into the LAA by stepwise pushing out the device from the delivery sheath. Subsequently, the sheath was withdrawn to expose the proximal cover, allowing it to expand in the left atrium and seal the LAA ostium. The LAmbre is a self-expanding nitinol-based device consisting of a fabric-enriched cover and an umbrella connected with a short central waist.
and exclusion criteria and were enrolled in the study.
Mean patient age was 69 years (range 42 to 86 years), and 56% were male. A history of paroxysmal AF was noted in 25 of 153 (16%) patients, persistent AF in 85 of 153 (56%) patients, and permanent AF in 43 of 152 (28%) patients. The most common risk factor for stroke was hypertension (73%), and 65% of patients previously had an ischemic stroke/transient ischemic attack. The average CHADS 2 score was 2.5, representing a 6.4% annual risk for stroke ( Figure 3) (18,19) .
The mean congestive heart failure, hypertension, age$75 years (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled)-. vascular disease, age 65 to 74 years, and sex category (female) (CHA 2 DS 2 -VASc) score was 4.0. On the basis of the CHA 2 DS 2 -VASc score, the expected annual risk for thromboembolism was 5.2% (20) . Table 1 showed the baseline characteristics of the study participants.
IMPLANTATION PROCEDURE. The LAA was successfully occluded by the LAmbre device in 152 patients (99.4%). In 87% of the successful cases, device implantation was managed with the first device selected, and in 9% or 3%, a second or third device, respectively, was needed. The implant was completely retrieved and redeployed in 43% patients.
The average angiographic maximal LAA diameter was 24 mm, and the mean LAA landing zone diameter was 23 mm ( Table 2 ). The distribution of successfully deployed devices is shown in Figure 4 . The mean procedure duration was 66 min, and the average contrast volume was 84 ml.
COMPLICATIONS. There were serious complications in 5 (3.3%) of the patients ( Table 3) The average CHADS 2 score of the study population was 2.5, representing a 6.4% annual risk for stroke. CHADS2 ¼ congestive heart failure, hypertension, age $75 years, diabetes mellitus, and prior stroke or transient ischemic attack.
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Huang et al. The size refers to the diameter of the umbrella and the cover, respectively. A total of 15 sizes were used, including 10 regular sizes (cover 4 to 6 mm larger) and 5 specific sizes (cover 12 to 14 mm larger). Values are n (%). Values are mean AE SD, %, or n (%).
LAA ¼ left atrial appendage.
LAmbre Prevents Stroke in AF Residual flow <1 mm 0
Residual flow 1-3 mm 18 (14.9)
Residual flow >3 mm 1 (0.8)
Values are n (%).
LAA ¼ left atrial appendage; TEE ¼ transesophageal echocardiography. LAmbre Prevents Stroke in AF 2193
